Fluvoxamine for the treatment of COVID-19
Lancet Glob Health
.
2022 Mar;10(3):e332.
doi: 10.1016/S2214-109X(22)00006-7.
Authors
Michael G Dodds
1
,
Eileen B Doyle
2
,
Angela M Reiersen
3
,
Fran Brown
1
,
Craig R Rayner
4
Affiliations
1
Certara, Princeton, NJ 08540, USA.
2
Certara, Princeton, NJ 08540, USA. Electronic address: eileen.doyle@certara.com.
3
Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.
4
Certara, Princeton, NJ 08540, USA; Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
PMID:
35180412
PMCID:
PMC8846600
DOI:
10.1016/S2214-109X(22)00006-7
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19 Drug Treatment*
Fluvoxamine* / therapeutic use
Humans
SARS-CoV-2
Substances
Fluvoxamine
Associated data
ClinicalTrials.gov/NCT04510194
ClinicalTrials.gov/NCT04885530